Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Gaia Klen is a private U.S. environmental biotechnology company focused on microorganism-based products for bioremediation, soil restoration, water purification, agricultural productivity, odor control, and fire suppression. The company was formed as Gaia Klen, LLC in Delaware in 2020 and has operated from High Point, North Carolina. Publicly available materials describe Gaia Klen as the exclusive worldwide provider of the Ergofito bioremediation product line licensed from South Africa-based Mavu Bio. Its offerings are positioned around natural, microbe-based formulations intended to remediate hydrocarbon contamination, improve wastewater treatment, support aquaculture and agriculture, and restore damaged ecosystems. Although founded by executives with pharmaceutical backgrounds and sometimes described in press materials as biotechnology-related, the business appears primarily environmental and agribiotech rather than healthcare-focused.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Gaia Klen.